Treatment of LNCaP cells with novel PRMT5:MEP50 protein:protein interaction inhibitors

ABSTRACT: We developed a novel compound for inhibition of PRMT5:MEP50 protein:protein interaction. LNCaP prostate cancer cells were treated with Compound 17 for 72 hours. Cells were harvested, RNA isolated, and then submitted for RNA-sequencing,

ORGANISM(S): Homo sapiens

PROVIDER: GSE206460 | GEO | 2025/06/17

REPOSITORIES: GEO